August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations. Reported EPS is $-0.98 EPS, expectations were $-0.66. Operator: Good morning, ladies and gentlemen, and welcome to the ...

The Trump administration’s move to reduce requirements has puzzled some legal experts while drawing applause from oil states.

We've all dreamed about sauntering up to the check-in counter, dressed to impress, praying that we'll be given that golden ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Kura Oncology missed GAAP revenue estimates in Q2 2025. Ziftomenib advanced to FDA Priority Review, hitting key clinical and regulatory milestones, with no product sales yet. Research and ...

The issue with placing it on the floodplain is that it reduces the available area for floodwaters to spread out and slow down,” one neighbor said.

COPENHAGEN - Ascendis Pharma A/S (NASDAQ: ASND) shares gained 2.9% after the biopharmaceutical company reported a narrower-than-expected second-quarter loss and revenue that exceeded analyst estimates ...